{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:51:47Z","timestamp":1772121107630,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Liver Institute"},{"DOI":"10.13039\/501100009403","name":"Menoufia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009403","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jpeds.2019.12.034","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T23:39:05Z","timestamp":1580427545000},"page":"106-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Safety and Efficacy of 8\u00a0Weeks Ledipasvir\/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10\u00a0Years"],"prefix":"10.1016","volume":"219","author":[{"given":"Behairy E.","family":"Behairy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanaa A.","family":"El-Araby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"El-Guindi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hosam-Eldin M.","family":"Basiouny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola A.","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassam A.","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman M.","family":"Marei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa M.","family":"Sira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2019.12.034_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jpeds.2019.12.034_bib2","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.3748\/wjg.v24.i38.4330","article-title":"Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations","volume":"24","author":"Omran","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jpeds.2019.12.034_bib3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/jhep.2001.20797","article-title":"Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity","volume":"33","author":"Habib","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jpeds.2019.12.034_bib4","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3748\/wjg.v13.i12.1828","article-title":"Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children","volume":"13","author":"El-Raziky","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jpeds.2019.12.034_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jpeds.2019.12.034_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MPG.0000000000001872","article-title":"Treatment of chronic hepatitis C virus infection in children: a position paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"66","author":"Indolfi","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2019.12.034_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/MPG.0000000000002101","article-title":"Sustained viral response in genotype 4 chronic hepatitis C virus-infected children and adolescents treated with sofosbuvir\/ledipasvir","volume":"67","author":"El-Karaksy","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2019.12.034_bib8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.dld.2018.09.012","article-title":"Is sofosbuvir\/ledipasvir safe for the hearts of children with hepatitis C virus?","volume":"51","author":"Ghobrial","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jpeds.2019.12.034_bib9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MPG.0000000000001968","article-title":"Dual sofosbuvir\/daclatasvir therapy in adolescent patients with chronic hepatitis C infection","volume":"67","author":"Yakoot","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2019.12.034_bib10","author":"US Food and Drug Administration"},{"key":"10.1016\/j.jpeds.2019.12.034_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/HMER.S113681","article-title":"Hepatitis C infection in Egypt: prevalence, impact and management strategies","volume":"9","author":"Gomaa","year":"2017","journal-title":"Hepat Med"},{"key":"10.1016\/j.jpeds.2019.12.034_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpeds.2019.12.034_bib13","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0168-8278(17)30377-X","article-title":"Ledipasvir\/sofosbuvir \u00b1 ribavirin for 12 or 24 weeks is safe and effective in children 6\u201311 years old with chronic hepatitis C infection","volume":"66","author":"Murray","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpeds.2019.12.034_bib14","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/apt.14677","article-title":"A pilot single arm observational study of sofosbuvir\/ledipasvir (200 + 45 mg) in 6- to 12- year old children","volume":"47","author":"El-Shabrawi","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2019.12.034_bib15","doi-asserted-by":"crossref","first-page":"14757","DOI":"10.1073\/pnas.1008877107","article-title":"Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt","volume":"107","author":"Miller","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpeds.2019.12.034_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1086\/345908","article-title":"Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children","volume":"36","author":"Jara","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jpeds.2019.12.034_bib17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/jvh.12668","article-title":"National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care","volume":"24","author":"El-Akel","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jpeds.2019.12.034_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4254\/wjh.v1.i1.67","article-title":"Hepatitis C virus and peripheral blood mononuclear cell reservoirs Patricia Bare","volume":"1","author":"Bare","year":"2009","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jpeds.2019.12.034_bib19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/MAJ.0b013e3181ec435e","article-title":"Detection of HCV RNA in the peripheral blood mononuclear cells of serum HCV RNA-negative Egyptian patients under interferon treatment","volume":"340","author":"Zayed","year":"2010","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jpeds.2019.12.034_bib20","first-page":"550","article-title":"Clearance of HCV RNA in peripheral blood mononuclear cell as a predictor of response to antiviral therapy in patients with chronic hepatitis C","volume":"4","author":"Xu","year":"2005","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.jpeds.2019.12.034_bib21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/vim.2017.0030","article-title":"The absence of HCV RNA and NS5A protein in peripheral blood mononuclear cells is a prognostic tool for sustained virological response","volume":"30","author":"Mehmood","year":"2017","journal-title":"Viral Immunol"},{"key":"10.1016\/j.jpeds.2019.12.034_bib22","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s00705-018-3922-7","article-title":"Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis","volume":"163","author":"Abd Alla","year":"2018","journal-title":"Arch Virol"},{"key":"10.1016\/j.jpeds.2019.12.034_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPG.0000000000001838","article-title":"Shortened 8 weeks course of dual sofosbuvir\/daclatasvir therapy in adolescent patients, with chronic hepatitis C infection","volume":"66","author":"El-Shabrawi","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2019.12.034_bib24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/gutjnl-2017-315906","article-title":"Ledipasvir\/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt","volume":"68","author":"Shiha","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jpeds.2019.12.034_bib25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.14218\/JCTH.2018.00014","article-title":"Hepatitis C virus clearance by direct-acting antiviral results in rapid resolution of hepatocytic injury as indicated by both alanine aminotransferase and aspartate aminotransferase normalization","volume":"6","author":"Huynh","year":"2018","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jpeds.2019.12.034_bib26","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/hep.30123","article-title":"Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6-11","volume":"68","author":"Murray","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jpeds.2019.12.034_bib27","first-page":"116A","article-title":"Ledipasvir\/sofosbuvir for 12 weeks is safe and effective in children 3 to <6 years old with chronic hepatitis C virus infection","volume":"86","author":"Schwarz","year":"2018","journal-title":"Hepatology"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347619317135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347619317135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:04:05Z","timestamp":1758359045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347619317135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":27,"alternative-id":["S0022347619317135"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2019.12.034","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737318630.793571050","asserted-by":"object"}]},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of 8\u00a0Weeks Ledipasvir\/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10\u00a0Years","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2019.12.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}